Global Cell Therapy Market Outlook 2020
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Pharmaceutical companies are actively looking for different modalities which could help in generating more revenues by competing with existing products. Traditional therapeutic have modest safety and efficacy levels and newer options are required to overcome their shortcomings. In this quest, they have focused upon cell therapy which holds both pharmacological and commercialization potential. Their utilization for therapeutic treatment of various diseases have been identified and used them successfully in past few decades. Various new cell therapy modalities are being discovered which are at different stages of clinical trials. They are expected to prove their safety and efficacy levels before entering in global market in coming years. Myriad of innovative cell therapies are under development which are expected to the change the way diseases are treated. Some of the therapeutics are widely accepted and they have already entered in clinical trials, while others are expected to face stringent regulations.
Cell therapies have been widely promoted by pharmaceutical companies as cure for all diseases. Especially, the concept of stem cell therapy has been promoted as panacea that can effectively tackle majority of ailments. But investigators have found that they are far from real scenario in which most of the underlying principles of stem cell therapy are not understood. During experimentation, investigators have found tumor formation in different parts of body of test subject. Microscopic examination revealed that it is not tumor nor cancerous cell accumulation, such thing has never been reported. In some cases, cancerous condition was found to be developed after administration of stem cells. These events show that server life threatening side effects could be developed without offering pharmacological benefits. Pharmaceutical companies need diligence because cells therapies are relatively new discovery and much work has to be done before their successful commercialization.
Utilization of cell therapy in tissue and regenerative medicine is expected to have huge marketing potential. Presently, there are no other options which could help in the growth of deregulated organs. Several therapeutic molecules are present in this segment but they are unable to form new tissue or sometimes organ transplant is required. It may be very complicated as suitable donor is required and process is quite invasive due to which high mortality rates are observed. On the other hand, cell therapy treatments are expected to overcome these issues which will increase their acceptance levels leading to higher sales. It could be applied for several categories that increase their applicability and commercialization prospects. Some categories like skin graft has been introduced across the globe for skin related issues. Presently, only few applications like severe burns are treated with their assistance but in future its applicability for cosmetic purposes are expected to be extended. In this way, their commercialization potential is expected to be improved increased due to increased number of indications.
Cell therapies are becoming competent with time and their utilization in large number of indications have made them an indispensible part of pharmaceutical industry. Significant investments in research and development segment along with years of data are helping in introduction of innovative products. However, they are quite new for pharmaceutical industry and their long-term effect is not known. It may offer hindrance but their superior pharmacological efficacy is going to promote their usage across the globe. It is at nascent stages but holds promise for future generations which are expected to observe boost in cell therapy products. Glitches in manufacturing and large scale production are needed to be solved in coming years. Many significant results have been achieved due to which confidence of investors, investigators, physicians and patients have increased in cell therapies. All these development shows that cell therapeutics are expected to generate significant revenues across the globe.
'Global Cell Therapy Market Outlook 2020' Report Highlight:
Pharmaceutical companies are actively looking for different modalities which could help in generating more revenues by competing with existing products. Traditional therapeutic have modest safety and efficacy levels and newer options are required to overcome their shortcomings. In this quest, they have focused upon cell therapy which holds both pharmacological and commercialization potential. Their utilization for therapeutic treatment of various diseases have been identified and used them successfully in past few decades. Various new cell therapy modalities are being discovered which are at different stages of clinical trials. They are expected to prove their safety and efficacy levels before entering in global market in coming years. Myriad of innovative cell therapies are under development which are expected to the change the way diseases are treated. Some of the therapeutics are widely accepted and they have already entered in clinical trials, while others are expected to face stringent regulations.
Cell therapies have been widely promoted by pharmaceutical companies as cure for all diseases. Especially, the concept of stem cell therapy has been promoted as panacea that can effectively tackle majority of ailments. But investigators have found that they are far from real scenario in which most of the underlying principles of stem cell therapy are not understood. During experimentation, investigators have found tumor formation in different parts of body of test subject. Microscopic examination revealed that it is not tumor nor cancerous cell accumulation, such thing has never been reported. In some cases, cancerous condition was found to be developed after administration of stem cells. These events show that server life threatening side effects could be developed without offering pharmacological benefits. Pharmaceutical companies need diligence because cells therapies are relatively new discovery and much work has to be done before their successful commercialization.
Utilization of cell therapy in tissue and regenerative medicine is expected to have huge marketing potential. Presently, there are no other options which could help in the growth of deregulated organs. Several therapeutic molecules are present in this segment but they are unable to form new tissue or sometimes organ transplant is required. It may be very complicated as suitable donor is required and process is quite invasive due to which high mortality rates are observed. On the other hand, cell therapy treatments are expected to overcome these issues which will increase their acceptance levels leading to higher sales. It could be applied for several categories that increase their applicability and commercialization prospects. Some categories like skin graft has been introduced across the globe for skin related issues. Presently, only few applications like severe burns are treated with their assistance but in future its applicability for cosmetic purposes are expected to be extended. In this way, their commercialization potential is expected to be improved increased due to increased number of indications.
Cell therapies are becoming competent with time and their utilization in large number of indications have made them an indispensible part of pharmaceutical industry. Significant investments in research and development segment along with years of data are helping in introduction of innovative products. However, they are quite new for pharmaceutical industry and their long-term effect is not known. It may offer hindrance but their superior pharmacological efficacy is going to promote their usage across the globe. It is at nascent stages but holds promise for future generations which are expected to observe boost in cell therapy products. Glitches in manufacturing and large scale production are needed to be solved in coming years. Many significant results have been achieved due to which confidence of investors, investigators, physicians and patients have increased in cell therapies. All these development shows that cell therapeutics are expected to generate significant revenues across the globe.
'Global Cell Therapy Market Outlook 2020' Report Highlight:
- Introduction & Classification of Cell Therapy
- Role of Stem Cells in Cell Therapy
- Global Cell Therapy Market Analysis
- Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
- Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication
- Global Cell Therapy Clinical Pipeline: 262 Cell Therapies
- Marketed Cell Therapies: 13
- Adipose Stem Cell Therapy (Adipocell)
- Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit)
- Angiogenic Cell Precursor Therapy (VesCell)
- Autologous Chondrocyte Implantation (ChondroCelect)
- Autologous Chondrocytes (BioCart)
- Autologous Cultured Chondrocyte Implant (Carticel)
- Autologous Cultured Chondrocytes (Chondrotransplant DISC)
- Matrix Characterised Autologous Cultured Chondrocytes (MACI)
- Azficel-T (Laviv)
- Human Skin Replacement for Burns (CellSpray)
- Leukocyte Cell Therapy (CureXcell)
- Sipuleucel-T (Provenge)
- T-Lymphocyte Cell Therapy (Immuncell-LC)
1. INTRODUCTION TO CELL THERAPY
2. CLASSIFICATION OF CELL THERAPIES
3. ROLE OF STEM CELLS IN CELL THERAPY
3.1 On the Basis of Ability to Differentiate
3.2 On the Basis of Origin
4. MECHANISM OF CELL THERAPY
5. GLOBAL CELL THERAPY MARKET ANALYSIS
5.1 Current Market Scenario
5.2 Cell Therapy Clinical Pipeline Overview
6. GLOBAL CELL THERAPY MARKET DYNAMICS
6.1 Favorable Market Parameters
6.2 Commercialization Challenges
7. GLOBAL CELL THERAPY MARKET FUTURE OUTLOOK
8. GLOBAL CELL THERAPY CLINICAL PIPELINE BY COUNTRY, INDICATION & PHASE
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-0
8.6 Phase-I
8.7 Phase-I/II
8.8 Phase-II
8.9 Phase-II/III
8.10 Phase-III
8.11 Preregistration
8.12 Registered
9. MARKETED CELL THERAPY CLINICAL INSIGHT BY BRAND NAME, COMPANY & INDICATION
9.1 Adipose Stem Cell Therapy (Adipocell)
9.2 Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit)
9.3 Angiogenic Cell Precursor Therapy (VesCell)
9.4 Autologous Chondrocyte Implantation (ChondroCelect)
9.5 Autologous Chondrocytes (BioCart)
9.6 Autologous Cultured Chondrocyte Implant (Carticel)
9.7 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
9.8 Matrix Characterised Autologous Cultured Chondrocytes (MACI)
9.9 Azficel-T (Laviv)
9.10 Human Skin Replacement for Burns (CellSpray)
9.11 Leukocyte Cell Therapy (CureXcell)
9.12 Sipuleucel-T (Provenge)
9.13 T-Lymphocyte Cell Therapy (Immuncell-LC)
10. DISCONTINUED & SUSPENDED CELL THERAPY IN CLINICAL PIPELINE
10.1 No Development Reported
10.2 Discontinued
10.3 Preregistration-Submission Withdrawal
10.4 Suspended
11. COMPETITIVE LANDSCAPE
11.1 AlloCure
11.2 Arteriocyte Medical Systems
11.3 Athersys Inc.
11.4 Baxter Healthcare Corporation
11.5 Bone Therapeutics
11.6 Celgene Corporation
11.7 Cell Medica
11.8 Cellerant Therapeutics
11.9 FibrocellScinence
11.10 Forticell Bioscience
11.11 Genzyme Corporation
11.12 Green Cross Cell
11.13 Histogenics Corporation
11.14 InnovacellBiotechnologie AG
11.15 Intrexon Corporation
11.16 Intercytex
11.17 ISTO Technologies
11.18 Macrocure
11.19 Mesoblast
11.20 Molmed
11.21 Nuo Therapeutics Inc
11.22 OmniCyte
11.23 Opexa Therapeutics
11.24 Organogenesis
11.25 Pharmicell
11.26 TCA Cellular Therapy
11.27 Stem Cell Inc.
11.28 Teva Pharmaceuticals
11.29 Tigenix
11.30 Vericel Corporation
2. CLASSIFICATION OF CELL THERAPIES
3. ROLE OF STEM CELLS IN CELL THERAPY
3.1 On the Basis of Ability to Differentiate
3.2 On the Basis of Origin
4. MECHANISM OF CELL THERAPY
5. GLOBAL CELL THERAPY MARKET ANALYSIS
5.1 Current Market Scenario
5.2 Cell Therapy Clinical Pipeline Overview
6. GLOBAL CELL THERAPY MARKET DYNAMICS
6.1 Favorable Market Parameters
6.2 Commercialization Challenges
7. GLOBAL CELL THERAPY MARKET FUTURE OUTLOOK
8. GLOBAL CELL THERAPY CLINICAL PIPELINE BY COUNTRY, INDICATION & PHASE
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-0
8.6 Phase-I
8.7 Phase-I/II
8.8 Phase-II
8.9 Phase-II/III
8.10 Phase-III
8.11 Preregistration
8.12 Registered
9. MARKETED CELL THERAPY CLINICAL INSIGHT BY BRAND NAME, COMPANY & INDICATION
9.1 Adipose Stem Cell Therapy (Adipocell)
9.2 Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit)
9.3 Angiogenic Cell Precursor Therapy (VesCell)
9.4 Autologous Chondrocyte Implantation (ChondroCelect)
9.5 Autologous Chondrocytes (BioCart)
9.6 Autologous Cultured Chondrocyte Implant (Carticel)
9.7 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
9.8 Matrix Characterised Autologous Cultured Chondrocytes (MACI)
9.9 Azficel-T (Laviv)
9.10 Human Skin Replacement for Burns (CellSpray)
9.11 Leukocyte Cell Therapy (CureXcell)
9.12 Sipuleucel-T (Provenge)
9.13 T-Lymphocyte Cell Therapy (Immuncell-LC)
10. DISCONTINUED & SUSPENDED CELL THERAPY IN CLINICAL PIPELINE
10.1 No Development Reported
10.2 Discontinued
10.3 Preregistration-Submission Withdrawal
10.4 Suspended
11. COMPETITIVE LANDSCAPE
11.1 AlloCure
11.2 Arteriocyte Medical Systems
11.3 Athersys Inc.
11.4 Baxter Healthcare Corporation
11.5 Bone Therapeutics
11.6 Celgene Corporation
11.7 Cell Medica
11.8 Cellerant Therapeutics
11.9 FibrocellScinence
11.10 Forticell Bioscience
11.11 Genzyme Corporation
11.12 Green Cross Cell
11.13 Histogenics Corporation
11.14 InnovacellBiotechnologie AG
11.15 Intrexon Corporation
11.16 Intercytex
11.17 ISTO Technologies
11.18 Macrocure
11.19 Mesoblast
11.20 Molmed
11.21 Nuo Therapeutics Inc
11.22 OmniCyte
11.23 Opexa Therapeutics
11.24 Organogenesis
11.25 Pharmicell
11.26 TCA Cellular Therapy
11.27 Stem Cell Inc.
11.28 Teva Pharmaceuticals
11.29 Tigenix
11.30 Vericel Corporation
LIST OF FIGURES
Figure 1-1: Benefits of Cell Therapy
Figure 1-2: Few Important Diseases for which Cell Therapies are Being Developed
Figure 1-3: Limitation of Cell Therapies
Figure 2-1: Classification of Cell Therapy on the Basis of Origin of Cells
Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
Figure 3-2: Type of Stem Cells on the Basis of Origin
Figure 4-1: Steps Involved in Development of Cell Therapies
Figure 4-2: Mechanism of Bone Marrow Transplantation
Figure 4-3: Mechanism of Pancreatic Therapy
Figure 4-4: Mechanism of Cardiac Cell Therapy
Figure 5-1: Global Cell Therapy Market (US$ Billion), 2012-2020
Figure 5-2: Global Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-3: Global Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-4: No Development Reported in Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-5: No Development Reported in Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-6: Discontinued Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-7: Discontinued Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-8: Suspended Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-9: Suspended Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 6-1: Global Cell Therapy Market Favorable Parameters
Figure 6-2: Cell Therapy Commercialization Challenges
Figure 11-1: Arteriocyte Medical Systems Clinical Pipeline
Figure 11-2: Bone Therapeutics Clinical Pipeline
Figure 11-3: Celgene Clinical Pipeline
Figure 11-4: Cellerant Therapeutics Clinical Pipeline
Figure 11-5: Fibrocell Science Clinical Pipeline
Figure 11-6: Genzyme Clinical Pipeline
Figure 11-7: Intrexon Clinical Pipeline
Figure 11-8: ISTO Clinical Pipeline
Figure 11-9: Mesoblast Clinical Pipeline
Figure 11-10: Molmed Clinical Pipeline
Figure 11-11: Pharmicell Clinical Pipeline
Figure 11-12: Tigenix Clinical Pipeline
Figure 11-13: Vericel Corporation Clinical Pipeline
Figure 1-1: Benefits of Cell Therapy
Figure 1-2: Few Important Diseases for which Cell Therapies are Being Developed
Figure 1-3: Limitation of Cell Therapies
Figure 2-1: Classification of Cell Therapy on the Basis of Origin of Cells
Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
Figure 3-2: Type of Stem Cells on the Basis of Origin
Figure 4-1: Steps Involved in Development of Cell Therapies
Figure 4-2: Mechanism of Bone Marrow Transplantation
Figure 4-3: Mechanism of Pancreatic Therapy
Figure 4-4: Mechanism of Cardiac Cell Therapy
Figure 5-1: Global Cell Therapy Market (US$ Billion), 2012-2020
Figure 5-2: Global Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-3: Global Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-4: No Development Reported in Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-5: No Development Reported in Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-6: Discontinued Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-7: Discontinued Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-8: Suspended Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-9: Suspended Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 6-1: Global Cell Therapy Market Favorable Parameters
Figure 6-2: Cell Therapy Commercialization Challenges
Figure 11-1: Arteriocyte Medical Systems Clinical Pipeline
Figure 11-2: Bone Therapeutics Clinical Pipeline
Figure 11-3: Celgene Clinical Pipeline
Figure 11-4: Cellerant Therapeutics Clinical Pipeline
Figure 11-5: Fibrocell Science Clinical Pipeline
Figure 11-6: Genzyme Clinical Pipeline
Figure 11-7: Intrexon Clinical Pipeline
Figure 11-8: ISTO Clinical Pipeline
Figure 11-9: Mesoblast Clinical Pipeline
Figure 11-10: Molmed Clinical Pipeline
Figure 11-11: Pharmicell Clinical Pipeline
Figure 11-12: Tigenix Clinical Pipeline
Figure 11-13: Vericel Corporation Clinical Pipeline
LIST OF TABLES
Table 2-1: Difference between Autogenic & Allogeneic Cell Therapy
Table 3-1: Difference between Embryonic, Adult & Induced Stem Cells
Table 2-1: Difference between Autogenic & Allogeneic Cell Therapy
Table 3-1: Difference between Embryonic, Adult & Induced Stem Cells
